Bora Biologics is proud to announce that it has received two prestigious honors at the 2025 IMAPAC Asia Pacific Biologics CDMO Excellence Awards, recognizing the company’s strengths in advanced biologics development and manufacturing.

Bora Biologics was named a winner in the following categories:

Best Biologics CDMO – Analytical Services
Best Biologics CDMO – Scale‑Up

The IMAPAC Asia Pacific Biologics CDMO Excellence Awards celebrate outstanding performance among contract development and manufacturing organizations across the biologics value chain. Winners are selected based on industry and customer voting, highlighting organizations that demonstrate technical excellence, innovation, and consistent delivery in critical service areas.

“We are honored to receive these awards and sincerely thank our customers for their trust and support,” said Marc Goemans, Chief Commercial Officer of Bora Biologics. “These recognitions underscore our commitment to providing robust analytical services and reliable scale‑up capabilities that help our partners advance their biologics programs with confidence.”

Bora Biologics also extends its gratitude to the Taiwan operations team, and to Jennifer Kuan, Vice President of Taiwan Operations, who accepted the awards on behalf of the company at the ceremony. These honors reflect the dedication, technical expertise, and collaborative spirit of the teams supporting clients across every stage of development and manufacturing.

Bora Biologics remains focused on advancing its analytical, scale‑up, and GMP manufacturing capabilities, delivering high‑quality, reliable solutions that support the evolving needs of global biopharmaceutical partners.

About Bora Biologics
Bora Biologics is a global CDMO offering agile, comprehensive end-to-end solutions for biopharma companies worldwide. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics leverages its state-of-the-art, FDA-registered facility in the U.S. and deep expertise in biologics development and manufacturing—including its own FDA-licensed and Health Canada approved product—to enhance time and cost efficiencies while ensuring effective pathways to market for its clients. Bora Biologics combines innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing and final packaging of clinical and commercial products.